Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07518186 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
NCT07518186 is a Phase 3 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 700 participants.
The verdict
NCT07518186, a Phase 3 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Interventions
- DRUG Teclistamab
- DRUG JNJ-79635322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2026-05-31 |
| Est. Completion | 2032-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07518186
The ClinicalTrials.gov registry entry for NCT07518186 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Teclistamab is the first listed.
NCT07518186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07518186 about?
NCT07518186 is a clinical study titled "A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
What is the current status of trial NCT07518186?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2026-05-31. Estimated completion is 2032-12-08.
What interventions are being tested in trial NCT07518186?
The interventions under investigation include: Teclistamab (DRUG), JNJ-79635322 (DRUG).
Who is sponsoring clinical trial NCT07518186?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.